Medix Biochemica expands its monoclonal antibody offering through the acquisition of Diaclone
- Medix Biochemica has acquired 100 percent of the shares of Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology.
- The acquisition expands Medix Biochemica’s leading portfolio of IVD raw materials, bringing complementary scientific and technological capabilities and strengthening the company’s local presence in Western Europe.
- As a result of the transaction, Diaclone’s product portfolio will be available through Medix Biochemica’s comprehensive global sales network.
Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Diaclone SAS (“Diaclone”) from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. Diaclone will become an important part of the Immunodiagnostic Reagents Business Unit within Medix Biochemica’s group structure, and its high-quality operations will continue in Besançon, France.
Founded in 1986, Diaclone is widely recognized for its expertise in the fields of inflammation, oncology and immunology. The company offers best-in-class monoclonal antibodies, high quality ELISA and ELISpot kits as well as custom services – ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies – to a broad range of IVD, life science, and pharma customers. Diaclone employs a team of ca. 25 professionals in Besançon, France.
“The acquisition of Diaclone is an important step towards our vision to be the first-choice, independent raw material partner for the IVD industry. The portfolio of Diaclone, including several gold standard antibodies, complements the offering of Medix Biochemica very well, and we are excited about the opportunity to offer these products to our global customer base. In addition, we see an excellent strategic and cultural fit with Medix Biochemica, and we value Diaclone’s technical and scientific competence highly. We look forward to jointly developing innovative and high-quality products to support our customers even better in the future”, says Steve Ferguson, CEO of Medix Biochemica.
“Following careful consideration, we concluded that it is the right time to find a new partner to support Diaclone’s future international growth. We are convinced that Medix Biochemica with its comprehensive reach to IVD customers globally, strong focus on quality and R&D and clear long-term vision, is the optimal new partner for Diaclone”, says Philippe Dulieu, President of Biotech Investissement Group.
Steve Ferguson, CEO of Medix Biochemica
Phone: +358 9 547 680
Medix Biochemica Group are a global, market-leading supplier of critical raw materials to the in vitro diagnostics (IVD) industry. Our mission is to enable IVD customers to deliver accurate results to billions of patients worldwide. By working in partnership with Medix Biochemica, IVD manufacturers can reduce their time to market through our industry-leading expertise which increases efficiencies and builds quality into their tests. We achieve this through our deep scientific know-how combined with the broadest and most relevant raw material portfolio and our relentless focus on quality.
Medix Biochemica Group employs more than 200 professionals worldwide. With headquarters in Finland, we serve our worldwide customers through our local teams in the US, Europe, and Asia. www.medixbiochemica.com